Myriad(US:MYGN)2025-08-05 20:30Q2 2025 Financial Performance - Q2 2025 revenue reached $213.1 million, driven by strong average revenue per test trends[6] - Adjusted gross margins in Q2 2025 were 71.5%, a year-over-year increase of 140 basis points[6] - Adjusted operating expenses in Q2 2025 grew by 2% year-over-year, reflecting a focus on managing discretionary spending[6] - Adjusted EBITDA for Q2 2025 was $14.5 million, representing a 24% year-over-year growth[6] - Adjusted EPS for Q2 2025 was $0.05[6] Revenue Growth and Guidance - The company is raising its 2025 revenue guidance range, with underlying total revenue growth of 5% year-over-year[9] - Oncology hereditary cancer test revenue grew by 9% year-over-year, driven by a 10% volume growth year-over-year[9] - Total potential liquidity is estimated at $205.9 million, including $74.4 million in cash and cash equivalents at the end of Q2 2025 and access to a new credit facility[44] Strategic Focus - The company is focusing on high-growth Cancer Care Continuum (CCC) segments to accelerate growth[9, 12, 14] - The company aims to grow revenue at or above market in Prenatal & Mental Health[9, 16] - The company is focused on sustained profitable growth[9, 12, 18]